To The Moon

🌟🌟🌟2025 had been a tale of 2 very different pharmaceutical fortunes.  On one side we have $Eli Lilly(LLY)$  soaring to new highs with a very smug 38.5% year todate gain, leaving a trail of exuberant investors in its wake.  On the other hand, there is poor old $Novo-Nordisk A/S(NVO)$  .  NVO had a rougher time, a truly stomach dropping ride down to 40% year todate .  This is largely due to intense competition, supply chain woes and profit warnings that sent investors running for the hills.

But wait!  Just when you thought NVO was down for the count, they pulled out their secret weapon: the FDA has approved the oral Wegovy pill this week.  It is the first and only oral GLP-1 therapy approved for chronic weight management.  It offers weight loss comparable to the popular injectable version, with a full US launch planned for early January 2026.

NVO Trend and Technical Analysis 

NVO is currently trading around USD 52.40 per share as of market close on December 26 2025, after a sharp move upward following the oral pill approval.  This action has potentially broken the stock's medium term falling trend channel, suggesting increased buyers' interest among investors.

Current Trend: Technical indicators signal a shift from a prolonged downtrend to a short term "Strong Buy".  The stock price is now above its 5, 50 and 200 day moving averages, a key bullish indicator.

Key Levels: Immediate support is around USD 48, while initial resistance is near USD 52.20, with the next level around USD 55.00.  A sustained break above these resistance levels would likely confirm a stronger, ongoing reversal.

Which is a Better Buy? Analyst Expectations 

Eli Lilly is the growth investor's ideal, trading at a premium valuation but offering market leadership, a strong diverse pipeline and expanding opportunities.  The consensus rating is a Buy with an average price target of USD 1,093.22.

Novo Nordisk is the classic value proposition, a dominant company currently trading at a discount after its year to date drop.  Analysts see potential for substantial returns if the turnaround succeeds, with a consensus Hold rating and an average price target of USD 53.51 for its US shares.  However some more bullish analysts see potential for over 50% upside if its valuation returns to historical norms.

Concluding Thoughts 

As we say good bye to 2025, the weight loss wars have moved from the pharmacy fridge to the medicine cabinet.  Whether you are riding the Eli Lilly rocket ship or betting on the Novo Nordisk redemption arc, one thing is clear: the market has a massive appetite for these 2 stocks , even if the patients taking them don't.

Will 2026 be the year the "Value Play" finally catches up with the "Growth King"?  Only time and possibly the next earnings call will tell.

Until then, keep your portfolios diversified, your stop losses tight and maybe just don't bet against a company that has just figured out how to put a blockbuster injection into a morning pill.

What's your play?  Are you team "Lilly to the Moon" or "Novo Comeback Kid"?  I vote Novo Comeback Kid!  Let's settle it in the comments.

@Tiger_comments  @TigerStars  @Tiger_SG  @TigerClub  @CaptainTiger